NS Pharma, Inc. (NSP) located in Paramus New Jersey is a subsidiary of Nippon Shinyaku Co., Ltd. 

Founded in 1999 in the United States, NSP is engaged in clinical studies and partnering with global pharmaceutical companies, venture companies and research institutes.

NSP serves as a contact point for connecting Japan/Asia and the world, developing drug candidates invented in Japan and out-license them to the world.   From the world to Japan/Asia, NSP in-license promising drug candidates to the Japanese/Asian Markets.

In coordination with parent company, Nippon Shinyaku, Co., Ltd., NSP will first and foremost develop and supply safe and highly effective pharmaceuticals through clinical studies.

NSP aims to be an indispensable entity in the healthcare industry in line with the guidelines for action “Challenge”, “Speed”, and “Investigation”. 


Life Sciences

Pharmaceutical

NS Pharma, Inc.

Yoshihiko Makita

Manabu Beppu

Koji Kimura

Tatsuaki Morokata

Takeshi Seita

Leslie Magnus

Gardner Gendron

The Patient Access and Market Engagement team at NS Pharma, Inc. is dedicated to ensuring that patients have timely access to innovative therapies. This team collaborates with healthcare providers, payers, and advocacy groups to navigate market access challenges, optimize pricing strategies, and enhance patient experiences. By focusing on patient services, strategic business solutions, and effective marketing, they aim to drive awareness and facilitate the delivery of NSP's pharmaceuticals to those who need them most.

Patient Access and Market Engagement

Clinical Research and Regulatory Affairs

Leadership Team

Patient Access and Market Engagement

About

Team members

Other teams at NS Pharma, Inc.

Clinical Research and Regulatory Affairs

Leadership Team